(Q50644048)

17 March 2018

title

Therapy effects of green tea in a patient with systemic light-chain amyloidosis. (English)

1 reference

17 March 2018

author

Derliz Mereles

series ordinal

1

1 reference

17 March 2018

Erich Wanker

series ordinal

2

1 reference

17 March 2018

Hugo A. Katus

series ordinal

3

object named as

Hugo A Katus

1 reference

17 March 2018

publication date

3 March 2008

1 reference

17 March 2018

Clinical Research in Cardiology

published in

1 reference

17 March 2018

volume

97

1 reference

17 March 2018

issue

5

1 reference

17 March 2018

page(s)

341-344

1 reference

17 March 2018

https://scigraph.springernature.com/pub.10.1007/s00392-008-0649-6

exact match

0 references

cites work

M-mode and two-dimensional echocardiographic features in cardiac amyloidosis

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00392-008-0649-6

Design, semisynthesis, and evaluation of O-acyl derivatives of (-)-epigallocatechin-3-gallate as antitumor agents.

21 January 2018

1 reference

12 December 2020

ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein

1 reference

12 December 2020

Longitudinal Myocardial Function Assessed by Tissue Velocity, Strain, and Strain Rate Tissue Doppler Echocardiography in Patients With AL (Primary) Cardiac Amyloidosis

1 reference

12 December 2020

Metabolism of green tea catechins: an overview

1 reference

12 December 2020

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis

1 reference

12 December 2020

Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice.

1 reference

12 December 2020

Transdermal delivery of (-)-epigallocatechin-3-gallate, a green tea polyphenol, in mice.

1 reference

12 December 2020

Eprodisate for the treatment of renal disease in AA amyloidosis.

1 reference

12 December 2020

Advances in the treatment of amyloidosis

1 reference

12 December 2020

Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option?

1 reference

12 December 2020

Long-term survival in a patient with AL amyloidosis after cardiac transplantation followed by autologous stem cell transplantation

1 reference

12 December 2020

A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent

1 reference

12 December 2020

Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies

1 reference

12 December 2020

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

1 reference

12 December 2020

10.1007/S00392-008-0649-6

Identifiers

DOI

1 reference

17 March 2018

1 reference

17 March 2018